Meeting
2017 ASCO Annual Meeting
Phase III randomized trial of image-guided bone marrow-sparing intensity modulated radiation therapy (IG-BMS-IMRT) for locoregionally advanced cervical cancer: The INTERTECC-3 trial.
Authors
Loren K. Mell
University of California San Diego Moores Cancer Center, La Jolla, CA
Loren K. Mell , Igor Sirak , Lorraine Portelance , Aaron Howard Wolfson , Alexandra J. Stewart , Dayanand Sharma , Denis Princ , Umesh Mahantshetty , Mitsuhiro Nakamura , Kimiko Hirata , Stephen F Kry , Lichun Wei , Ronghui Xu , Kaveh Zakeri , Elena Sojourner , Kevin Moore , Michael T. McHale , Cheryl C. Saenz , Catheryn M. Yashar , Arno James Mundt
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Cervical Cancer
Clinical Trial Registration Number
NCT01554397
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS5600)
DOI
10.1200/JCO.2017.35.15_suppl.TPS5600
Abstract #
TPS5600
Poster Bd #
422a
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Randomized phase III trial of gemcitabine and cisplatin versus gemcitabine alone in patients with advanced non-small cell lung cancer (NSCLC) and a performance status (PS) 2: CAPPA-2 study.
First Author: Alessandro Morabito
Poster
2021 ASCO Annual Meeting
Phase III study of NUC-1031 + cisplatin versus gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121).
First Author: Jennifer J. Knox
Poster
2021 Gastrointestinal Cancers Symposium
Phase III study of NUC-1031 + cisplatin vs gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121).
First Author: Jennifer J. Knox